生物制剂治疗在老年免疫介导性疾病患者中的安全性:系统评价与Meta分析
该系统评价与Meta分析纳入14项研究,比较老年(>60岁)与年轻生物制剂使用者及老年非使用者的安全性,发现老年使用者感染风险显著升高(合并OR 2.28,95%CI 1.57-3.31 vs 年轻使用者;OR 3.60,95%CI 1.62-8.01 vs 老年非使用者),恶性肿瘤风险较年轻使用者升高(OR 3.07,95%CI 1.98-4.62),但与老年非使用者相比恶性肿瘤和死亡风险无显著差异。
要点
- 老年生物制剂使用者感染合并患病率13%,年轻使用者为6%,合并OR 2.28(95%CI 1.57-3.31)。
- 老年使用者较年轻使用者恶性肿瘤风险升高(OR 3.07,95%CI 1.98-4.62)。
- 老年使用者较老年非使用者感染风险升高(OR 3.60,95%CI 1.62-8.01),恶性肿瘤和死亡风险无显著差异。
核心结论
- 老年生物制剂使用者较年轻使用者或老年非使用者感染风险升高。
- 需大规模前瞻性队列研究评估老年免疫介导性疾病患者生物制剂治疗的安全性。
研究设计与样本
- 系统检索PubMed/Medline和Embase,纳入14项独特研究。
- 纳入老年(>60岁)开始生物制剂治疗者4719例、年轻生物制剂使用者13305例、老年非生物制剂使用者3961例。
- 采用DerSimonian and Laird随机效应模型计算合并OR和95%CI。
主要发现
- 老年与年轻生物制剂使用者感染合并患病率分别为13%和6%,合并随机效应OR 2.28(95%CI 1.57-3.31)。
- 老年较年轻使用者恶性肿瘤风险显著升高(OR 3.07,95%CI 1.98-4.62)。
- 老年使用者较老年非使用者感染风险升高约3倍(OR 3.60,95%CI 1.62-8.01)。
- 老年使用者与老年非使用者相比,恶性肿瘤(OR 0.54,95%CI 0.28-1.05)和死亡(OR 1.52,95%CI 0.44-5.28)风险无显著差异。
局限性
- 需大规模前瞻性队列研究评估老年免疫介导性疾病患者生物制剂治疗的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Management of immune-mediated inflammatory diseases often requires lifelong immunosuppression. Increasing numbers of older patients have inflammatory diseases and are particularly vulnerable to risks of immune suppressive therapies-particularly infections and malignancies. METHODS: We systematically searched PubMed/Medline and Embase to identify eligible studies that examined the safety of biologic therapies in older patients with immune-mediated inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis, psoriasis). Included studies provided information on patients who began receiving therapy with a biologic agent when they were older than 60 years and a control population (either younger users of biologics or older patients who did not use biologics). Information of on overall pooled rates of infections, malignancy, and mortality were extracted. A DerSimonian and Laird random effects model was used to calculate pooled odds ratios (ORs) and 95% CIs. RESULTS: Our meta-analysis included 14 unique studies that comprised 4719 older users of biologics, 13,305 younger users of biologics, and 3961 older patients who did not use biologics. The pooled prevalence of infections in older and younger users of biologics was 13% and 6% respectively, yielding a pooled random effects odds ratio of 2.28 (95% CI, 1.57-3.31). Older age was associated with a significant increase in risk of malignancy (OR, 3.07; 95% CI, 1.98-4.62) compared to younger age. Older users of biologics had a 3-fold increase in risk of infection compared to patients who did not use biologics (OR, 3.60; 95% CI, 1.62-8.01), but there were no significant differences in odds of malignancy (0.54, 95% CI, 0.28-1.05) or death (OR, 1.52; 95% CI, 0.44-5.28) compared to older patients who did not use biologics. CONCLUSION: In a systematic review and meta-analysis of studies on the safety of biologic therapies in older patients with inflammatory diseases, we found that older users of biologic agents have an increased risk of infections compared with younger users or older patients who do not use biologics. Large, prospective cohort studies are needed to examine safety of biologic therapy in older patients with immune-mediated diseases.
引用
- Borren NZ, Ananthakrishnan AN. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019. PMID: 30616024. doi:10.1016/j.cgh.2018.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。